Quantcast

Latest Multiple Myeloma Research Consortium Stories

2008-11-06 15:00:28

The International Myeloma Foundation (IMF)--supporting research and providing education, advocacy and support for myeloma patients, families, researchers and physicians--today called for all patients to have access to the newest pharmaceuticals making life-changing advances in the treatment of myeloma. REVLIMID(R), THALOMID(R) (global thalidomide) and VELCADE(R), known collectively as the "novel therapies," have extended survival and improved quality of life for patients with the blood...

2008-10-14 09:00:44

The Multiple Myeloma Research Consortium has initiated a three-drug combination study of elotuzumab, a humanized anti-CS1 monoclonal IgG1 antibody administered intravenously, in combination with Revlimid, and dexamethasone for the treatment of multiple myeloma in patients who are experiencing a relapse. Emory University's Winship Cancer Institute, Washington University, and St Vincent's Comprehensive Cancer Center of Saint Vincent Catholic Medical Centers of New York will evaluate the...

2008-10-13 12:00:41

The Multiple Myeloma Research Consortium (MMRC) today announced the initiation of a three-drug combination study of elotuzumab (also known as HuLuc63), a humanized anti-CS1 monoclonal IgG1 antibody administered intravenously, in combination with REVLIMID(R) (lenalidomide), and dexamethasone for the treatment of multiple myeloma in patients who are experiencing a relapse. Emory University's Winship Cancer Institute, Washington University, and St. Vincent's Comprehensive Cancer Center of...

2008-08-25 12:01:19

The Multiple Myeloma Research Consortium has started a Phase I/II clinical trial with the oral immunomodulatory agent pomalidomide in patients who have received at least two prior therapies including treatments with Revlimid and Velcade for injection. The Phase I study is designed to determine maximum tolerated dose of single-agent pomalidomide while the Phase II randomized study will compare the oral compound's efficacy alone against its combination with dexamethasone. Paul Richardson,...

2008-08-22 18:00:43

The Multiple Myeloma Research Consortium (MMRC) today announced the initiation of a clinical trial with the oral immunomodulatory agent pomalidomide (CC-4047) in patients who have received at least two prior therapies including treatments with REVLIMID(R) (lenalidomide) and VELCADE(R) (bortezomib) for Injection. Paul Richardson, MD, Clinical Director of the Jerome Lipper Center for Multiple Myeloma at Dana-Farber Cancer Institute, is leading the Phase 1 / 2, multicenter, randomized,...

2008-08-13 09:01:15

The Multiple Myeloma Research Consortium (MMRC) today announced the initiation of a four-drug combination study with REVLIMID(R) (lenalidomide), VELCADE(R) (bortezomib) for Injection, DOXIL(R) (doxorubicin HCl liposome injection) and dexamethasone for the treatment of multiple myeloma in patients who are previously untreated. The University of Michigan, one of fifteen MMRC member institutions, will evaluate the safety and efficacy of the drug combination in patients who have not received...

2008-07-18 15:00:57

The Multiple Myeloma Research Consortium (MMRC) today announced the initiation of a Phase I/II study of elotuzumab (also known as Huluc63), a humanized anti-CS1 monoclonal IgG1 antibody administered intravenously, in combination with VELCADE(R) (bortezomib) for Injection for the treatment of relapsed multiple myeloma. This study, sponsored by PDL BioPharma, Inc., and conducted at the following MMRC Member Institutions: the University of Michigan, Dana-Farber Cancer Institute, University...

2008-07-10 09:01:29

SOUTH SAN FRANCISCO, Calif., July 10 /PRNewswire/ -- Proteolix, Inc. today announced that patient dosing has commenced in a Phase 1b clinical trial to evaluate the safety and efficacy of Proteolix's lead anti-cancer agent, carfilzomib (PR-171), in combination with lenalidomide and dexamethasone in patients with relapsed multiple myeloma. Carfilzomib selectively blocks proteasome activity, causing apoptosis in cancer cells. In single agent Phase 1 studies carfilzomib has demonstrated...

2008-06-27 15:03:00

The Multiple Myeloma Research Consortium (MMRC) today announced the addition of two Member Institutions. The new institutions, Indiana University Simon Cancer Center in Indianapolis and the University of California, San Francisco (UCSF), were selected following a highly competitive Request for Application (RFA) process. The MMRC's current 13 Member Institutions are among the world's most prestigious academic research institutions. Indiana University and UCSF were selected to join the...

2006-01-09 09:03:39

SAN FRANCISCO (Reuters) - Celgene Corp. said on Monday that a pivotal-stage trial of its Thalomid drug was stopped early after the medicine was shown to dramatically limit the progress of the blood cancer multiple myeloma. The drug, also known as thalidomide, was first introduced in the 1950s and became notorious for causing birth defects. It is currently approved for treating a symptom of leprosy. The Phase 3 trial of 270 patients found that that it took an average of 75.7 weeks for...


Word of the Day
cock-a-hoop
  • Exultant; jubilant; triumphant; on the high horse.
  • Tipsy; slightly intoxicated.
This word may come from the phrase 'to set cock on hoop,' or 'to drink festively.' Its origin otherwise is unclear. A theory, according to the Word Detective, is that it's a 'transliteration of the French phrase 'coq a huppe,' meaning a rooster displaying its crest ('huppe') in a pose of proud defiance.' Therefore, 'cock-a-hoop' would 'liken a drunken man to a boastful and aggressive rooster.'
Related